Intercept Pharmaceuticals Stock Forecast, Price & News

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intercept Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 15 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Intercept Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ICPT, but not buy additional shares or sell existing shares.
View analyst ratings for Intercept Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Intercept Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intercept Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Intercept Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Intercept Pharmaceuticals.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) announced its quarterly earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($1.58) EPS for the quarter, missing the Zacks' consensus estimate of ($1.55) by $0.03. The biopharmaceutical company earned $83.27 million during the quarter, compared to the consensus estimate of $84.10 million. Intercept Pharmaceuticals had a negative net margin of 106.64% and a negative trailing twelve-month return on equity of 1,973.10%.
View Intercept Pharmaceuticals' earnings history.

Intercept Pharmaceuticals' stock was trading at $77.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ICPT stock has decreased by 72.7% and is now trading at $21.20.
View which stocks have been most impacted by COVID-19.

Intercept Pharmaceuticals issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, March, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $325-355 million, compared to the consensus revenue estimate of $341.19 million.

24 equities research analysts have issued 1-year target prices for Intercept Pharmaceuticals' stock. Their forecasts range from $21.00 to $88.00. On average, they anticipate Intercept Pharmaceuticals' share price to reach $50.70 in the next twelve months. This suggests a possible upside of 139.1% from the stock's current price.
View analysts' price targets for Intercept Pharmaceuticals or view top-rated stocks among Wall Street analysts.

32 employees have rated Intercept Pharmaceuticals CEO Mark Pruzanski on Glassdoor.com. Mark Pruzanski has an approval rating of 80% among Intercept Pharmaceuticals' employees.

Some companies that are related to Intercept Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), United Therapeutics (UTHR) and Neurocrine Biosciences (NBIX).
View all of ICPT's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intercept Pharmaceuticals investors own include Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), Tesla (TSLA), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), Ionis Pharmaceuticals (IONS), Regeneron Pharmaceuticals (REGN) and Biogen (biib).

Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."

Intercept Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Pacer Advisors Inc. (0.01%). Company insiders that own Intercept Pharmaceuticals stock include Christian Weyer, David A Ford, David Shapiro, Gail Cawkwell, Jason Campagna, Lisa Bright, Luca Benatti, Mark Pruzanski, Paolo Fundaro, Ryan T Sullivan, Sandip Kapadia, SPA Genextra and Srinivas Akkaraju.
View institutional ownership trends for Intercept Pharmaceuticals.

ICPT stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Christian Weyer, Jason Campagna, Paolo Fundaro, Sandip Kapadia, and SPA Genextra.
View insider buying and selling activity for Intercept Pharmaceuticals or view top insider-selling stocks.

Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ICPT stock can currently be purchased for approximately $21.20.

Intercept Pharmaceuticals has a market capitalization of $703.03 million and generates $252 million in revenue each year. The biopharmaceutical company earns $-344,680,000.00 in net income (profit) each year or ($10.89) on an earnings per share basis.

Intercept Pharmaceuticals employs 498 workers across the globe.

The official website for Intercept Pharmaceuticals is www.interceptpharma.com.

Intercept Pharmaceuticals is headquartered at 10 Hudson Yards 37th FL, New York NY, 10001.

Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]